TY - JOUR
T1 - Kinetics of the use of cryopreserved autologous stem cell grafts
T2 - A GITMO-SIDEM survey
AU - Olivieri, Jacopo
AU - Pierelli, Luca
AU - Introna, Martino
AU - Accorsi, Patrizia
AU - Bosi, Alberto
AU - Perseghin, Paolo
AU - Risso, Marco
AU - Pandolfi, Annino
AU - Mancini, Stefania
AU - Marchetti, Monia
AU - Dal Pozzo, Simone
AU - Gotti, Elisa
AU - Rambaldi, Alessandro
AU - Leoni, Pietro
AU - Olivieri, Attilio
PY - 2014/1
Y1 - 2014/1
N2 - Background aims: Hematopoietic stem cell cryopreservation significantly contributed to autologous stem cell transplantation (ASCT). Cryopreserved stem cell units (SCU) are expected to be used soon after harvesting for most purposes, but, in a number of cases, they remain stored for some time, creating an increasing load for SCU depositories. Disposal policies vary widely in each center, and the existing guidelines are insufficient. Methods: We conducted a survey of seven Gruppo Italiano Trapianto di Midollo Osseo centers to investigate the outcome of SCU harvested from January 2005 to December 2009 for ASCT. The data from 1603 collections were gathered, for a total of 5822 SCU. Results: In our cohort, 79% of patients collected >5× 106 CD34+ cells/kg, and 3.4% collected6 CD34+ cells/kg. Up to 21% of all the patients and 42% of those with acute leukemia did not undergo reinfusion, and 37% of the cryopreserved SCU were excess, resulting from patients not reinfusing or partially reinfusing. Less than one-third of the excess SCU was disposed, and the major causes of disposal were death and, in a minority of cases, withdrawal of the indication for ASCT. In our analysis, very few first reinfusions occurred after 2 years, and those after 5 years were exceptional. Through the use of a multivariate analysis, we sought to identify the risk factors for collection non-use, independent of the centers' policies. Non-use of SCU was significantly associated with patients with acute leukemia, collections of6 CD34/kg and lower age groups. Conclusions: These dataserve as a valid basis to support rational recommendations for cost-effective storage and disposal of SCU.
AB - Background aims: Hematopoietic stem cell cryopreservation significantly contributed to autologous stem cell transplantation (ASCT). Cryopreserved stem cell units (SCU) are expected to be used soon after harvesting for most purposes, but, in a number of cases, they remain stored for some time, creating an increasing load for SCU depositories. Disposal policies vary widely in each center, and the existing guidelines are insufficient. Methods: We conducted a survey of seven Gruppo Italiano Trapianto di Midollo Osseo centers to investigate the outcome of SCU harvested from January 2005 to December 2009 for ASCT. The data from 1603 collections were gathered, for a total of 5822 SCU. Results: In our cohort, 79% of patients collected >5× 106 CD34+ cells/kg, and 3.4% collected6 CD34+ cells/kg. Up to 21% of all the patients and 42% of those with acute leukemia did not undergo reinfusion, and 37% of the cryopreserved SCU were excess, resulting from patients not reinfusing or partially reinfusing. Less than one-third of the excess SCU was disposed, and the major causes of disposal were death and, in a minority of cases, withdrawal of the indication for ASCT. In our analysis, very few first reinfusions occurred after 2 years, and those after 5 years were exceptional. Through the use of a multivariate analysis, we sought to identify the risk factors for collection non-use, independent of the centers' policies. Non-use of SCU was significantly associated with patients with acute leukemia, collections of6 CD34/kg and lower age groups. Conclusions: These dataserve as a valid basis to support rational recommendations for cost-effective storage and disposal of SCU.
KW - Biological specimen banks
KW - Cryopreservation
KW - Hematopoietic progenitor cells
KW - Hematopoietic stem cell transplantation
KW - Long-term storage
KW - Medical waste disposal
UR - http://www.scopus.com/inward/record.url?scp=84890972582&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84890972582&partnerID=8YFLogxK
U2 - 10.1016/j.jcyt.2013.07.001
DO - 10.1016/j.jcyt.2013.07.001
M3 - Article
C2 - 24169075
AN - SCOPUS:84890972582
VL - 16
SP - 101
EP - 110
JO - Cytotherapy
JF - Cytotherapy
SN - 1465-3249
IS - 1
ER -